Laura Bey - SkinBioTherapeutics Head Formulations
| SBTX Stock | 15.88 0.12 0.75% |
Executive
Laura Bey is Head Formulations of SkinBioTherapeutics PLC
| Address | The Core, Newcastle upon Tyne, United Kingdom, NE4 5TF |
| Phone | 44 19 1495 7325 |
| Web | https://www.skinbiotherapeutics.com |
SkinBioTherapeutics Management Efficiency
The company has return on total asset (ROA) of (0.6118) % which means that it has lost $0.6118 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1864) %, meaning that it generated substantial loss on money invested by shareholders. SkinBioTherapeutics' management efficiency ratios could be used to measure how well SkinBioTherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, SkinBioTherapeutics' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 3.1 M in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (746.8 K).Similar Executives
| Found 7 records | EXECUTIVE Age | ||
| Kelly McGrath | Malvern International | N/A | |
| James Gordon | Quantum Blockchain Technologies | N/A | |
| Steve Guse | Hardide PLC | N/A | |
| Alistair Stobie | Tungsten West PLC | 58 | |
| Stephen Harvey | Malvern International | N/A | |
| Jackie Robinson | Hardide PLC | N/A | |
| Daniele Pluchino | Malvern International | N/A | |
Management Performance
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.61 |
SkinBioTherapeutics PLC Leadership Team
Elected by the shareholders, the SkinBioTherapeutics' board of directors comprises two types of representatives: SkinBioTherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SkinBioTherapeutics. The board's role is to monitor SkinBioTherapeutics' management team and ensure that shareholders' interests are well served. SkinBioTherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SkinBioTherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Catherine ONeill, Chief Board | ||
| Manprit Randhawa, Chief Officer | ||
| Stuart Ashman, CEO Director | ||
| Melissa Greenwell, Group Controller | ||
| Douglas Quinn, Company Sec | ||
| Laura Bey, Head Formulations |
SkinBioTherapeutics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SkinBioTherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.61 | ||||
| Operating Margin | (13.01) % | ||||
| Current Valuation | 33.81 M | ||||
| Shares Outstanding | 228.44 M | ||||
| Shares Owned By Insiders | 19.32 % | ||||
| Shares Owned By Institutions | 16.45 % | ||||
| Price To Book | 10.01 X | ||||
| Price To Sales | 226.11 X | ||||
| Revenue | 132.06 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SkinBioTherapeutics Stock Analysis
When running SkinBioTherapeutics' price analysis, check to measure SkinBioTherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SkinBioTherapeutics is operating at the current time. Most of SkinBioTherapeutics' value examination focuses on studying past and present price action to predict the probability of SkinBioTherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SkinBioTherapeutics' price. Additionally, you may evaluate how the addition of SkinBioTherapeutics to your portfolios can decrease your overall portfolio volatility.